AdetolaAKassimMD
Hematology • Nashville, TNProfessor of Medicine, Vanderbilt University School of Medicine
Dr. Kassim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-936-8422Fax+1 615-322-7772
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1996 - 1998
Icahn School of Medicine at Mount Sinai (North General)Residency, Internal Medicine, 1992 - 1995
University of Lagos College of MedicineClass of 1988
Certifications & Licensure
TN State Medical License 2001 - 2025
AL State Medical License 2020 - 2020
NJ State Medical License 1996 - 2005
AZ State Medical License 2003 - 2004- American Board of Internal Medicine Hematology
Clinical Trials
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
- Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant Start of enrollment: 2003 Apr 01
- Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant Start of enrollment: 2003 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 109 citationsSilent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia.Adetola A. Kassim, Sumit Pruthi, Matthew A. Day, Mark Rodeghier, Melissa C. Gindville
Blood. 2014-12-06 - 19 citationsMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaRobert F. Cornell, Anita D'Souza, Adetola A. Kassim, Luciano J. Costa, Racquel Innis-Shelton
Biology of Blood and Marrow Transplantation. 2017-02-01 - 73 citationsPrevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria.Ryan Jacobs, U Tran, Heidi Chen, Adetola A. Kassim, Brian G. Engelhardt
Bone Marrow Transplantation. 2012-04-09
Abstracts/Posters
- Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I N...Adetola A. Kassim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Sickle Cell Disease Post-Transplant Care Challenges in Nigeria: Systematic Institutional Neglect of Medical TourismAdetola A. Kassim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid LeukemiaAdetola A. Kassim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Meet Michael DeBaun, MD, MPH – Maryville Board of TrusteesSeptember 15th, 2020
Patient’s Efforts Help Shine Light on Plasma Cell DisorderApril 5th, 2018- A Cure for Sickle Cell DiseaseDecember 14th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
